Becton Dickinson (NYSE:BDX) today said it appointed Patrick Kaltenback as executive VP and chief technology officer and Dave Hickey as EVP and president of life sciences, both effective Jan. 1, 2021.
Kaltenbach will be responsible for driving the company’s category innovation strategy and leading research and development activities, which includes executing the innovation pipeline and developing a future product portfolio.
He previously served as the company’s president of the life sciences segment. Prior to joining the company, Kaltenbach was senior VP of Agilent and president of its life sciences and applied markets group. He has also held leadership roles at Hewlett-Packard.
“Patrick has distinguished himself throughout nearly three decades in R&D management and business leadership, making him an ideal candidate to continue our drive toward category innovation in alignment with our strategy to grow, simplify and empower,” president and CEO Tom Polen said in a news release. “In his time at BD, Patrick has been a thoughtful and enterprising leader, bringing a strong external orientation to help inform our strategy and best position BD to drive growth. He has done outstanding work accelerating the R&D pipeline and unlocking value in the Life Sciences segment, most recently working to ensure our life sciences team was well-positioned to support the world’s response to COVID-19 through a portfolio of innovative diagnostics solutions.”
Following Kaltenbach’s promotion, BD named Hickey as executive VP and president of life sciences at the company. He currently serves as the worldwide president of integrated diagnostic solutions.
Hickey will be responsible for overseeing biosciences, preanalytical systems and diagnostics systems businesses worldwide.
“I’m confident Dave is the right successor to lead the life sciences segment at this critical time for the industry and for public health,” Polen said. “Throughout nearly 30 years of experience in the life sciences field, Dave has consistently delivered high performance and he has proven himself as an empathetic, passionate and transformative leader of customer-centric teams. Dave’s leadership in the Diagnostics space has been on full display during the pandemic, as his team rallied around our purpose and delivered innovative laboratory and point-of-care COVID-19 testing solutions in record time.”
Hickey previously joined the company as VP and GM of the clinical microbiology business. Prior to BD, he held numerous leadership roles with Siemens Healthcare Diagnostics.
Kaltenbach and Hickey will both report directly to Polen.